Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
PrECOG, LLC.
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07637513CT.gov Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT05403723CT.gov Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC | — | Suspended | — | — | — |
NCT07459634CT.gov A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC | — | Not Yet Recruiting | — | — | — |
NCT07339059CT.gov Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07531095CT.gov Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) | — | Recruiting | — | — | — |
NCT07055581CT.gov Durvalumab as Consolidation for Patients LS-SCLC | — | Recruiting | — | — | — |
NCT07149363CT.gov Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06769126CT.gov Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study | — | Recruiting | — | — | — |
NCT07172412CT.gov Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07174583CT.gov A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | — | Recruiting | — | — | — |
Show 62 more trialsShow fewer
NCT06992609CT.gov Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer. | — | Recruiting | — | — | — |
NCT07005128CT.gov A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) | — | Recruiting | — | — | — |
NCT06939036CT.gov Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) | — | Terminated | — | — | — |
NCT06898957CT.gov Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) | — | Active Not Recruiting | — | — | — |
NCT06287775CT.gov Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06773910CT.gov BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) | — | Recruiting | — | — | — |
NCT06780137CT.gov A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | — | Recruiting | — | — | — |
NCT06869239CT.gov Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy | — | Recruiting | — | — | — |
NCT06719336CT.gov Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001) | — | Not Yet Recruiting | — | — | — |
NCT06419179CT.gov Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) | — | Enrolling By Invitation | — | — | — |
NCT06826677CT.gov REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER | — | Completed | — | — | — |
NCT06429696CT.gov PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06211036CT.gov Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab | — | Active Not Recruiting | — | — | — |
NCT05161533CT.gov Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial | — | Withdrawn | — | — | — |
NCT06223711CT.gov Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC | — | Recruiting | — | — | — |
NCT05572476CT.gov Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer | — | Withdrawn | — | — | — |
NCT05903092CT.gov MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06371482CT.gov Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01) | — | Recruiting | — | — | — |
NCT05617963CT.gov Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax | — | Active Not Recruiting | — | — | — |
NCT05668767CT.gov Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC | — | Unknown | — | — | — |
NCT05683977CT.gov A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer. | — | Active Not Recruiting | — | — | — |
NCT05361395CT.gov First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | — | Active Not Recruiting | — | — | — |
NCT05068232CT.gov Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) | — | Recruiting | — | — | — |
NCT05484583CT.gov Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases | — | Not Yet Recruiting | — | — | — |
NCT04397003CT.gov Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05092412CT.gov Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC | — | Active Not Recruiting | — | — | — |
NCT05223647CT.gov Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer | — | Terminated | — | — | — |
NCT05796089CT.gov Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy | — | Active Not Recruiting | — | — | — |
NCT04774380CT.gov Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT04985851CT.gov To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS. | — | Unknown | — | — | — |
NCT05034133CT.gov Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05245994CT.gov An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese | — | Unknown | — | — | — |
NCT04951115CT.gov A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04538378CT.gov Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors | — | Terminated | — | — | — |
NCT04870112CT.gov A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04472949CT.gov Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). | — | Active Not Recruiting | — | — | — |
NCT04660097CT.gov Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer | — | Completed | — | — | — |
NCT04699838CT.gov Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT04745689CT.gov Study of AZD2811 + Durvalumab in ES-SCLC | — | Active Not Recruiting | — | — | — |
NCT04728230CT.gov Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial | — | Active Not Recruiting | — | — | — |
NCT04602533CT.gov Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) | — | Active Not Recruiting | — | — | — |
NCT04712903CT.gov Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT04449861CT.gov Durvalumab Plus Chemotherapy in ES-SCLC (Oriental) | — | Completed | — | — | — |
NCT04607954CT.gov Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT03963414CT.gov A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC | — | Terminated | — | — | — |
NCT04525391CT.gov AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04504669CT.gov First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | — | Completed | — | — | — |
NCT04672759CT.gov A Real-world Study of Durvalumab for Lung Cancer in China | — | Unknown | — | — | — |
NCT04361825CT.gov Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects | — | Completed | — | — | — |
NCT04285866CT.gov Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy. | — | Completed | — | — | — |
NCT04314297CT.gov Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study | — | Unknown | — | — | — |
NCT03923270CT.gov Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT03228667CT.gov QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT03703297CT.gov Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy | — | Active Not Recruiting | — | — | — |
NCT03585998CT.gov Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03509012CT.gov Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03085849CT.gov SGI-110 Plus Durvalumab/Tremelimumab in SCLC | — | Completed | — | — | — |
NCT03043872CT.gov Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) | — | Active Not Recruiting | — | — | — |
NCT02937818CT.gov A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer | — | Completed | — | — | — |
NCT02658214CT.gov Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | — | Completed | — | — | — |
NCT02701400CT.gov Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02734004CT.gov A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Durvalumab (this asset) | PrECOG, LLC. | P3 | BB · 66 |
| Benmelstobart | Yayi He | P4 | A |
| Anti-Pd-L1 Monoclonal Antibody Shr-1316 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BBB |
| Berzosertib | National Cancer Institute (NCI) | P2 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Etoposide | Sichuan University | P4 | BBB |
| Veliparib | Central European Society for Anticancer Drug Research | P2 | BB |
| Carboplatin | University of Maryland, Baltimore | P4 | BB |
| Nogitecan | AbbVie | P4 | BB |
+42 more in the Small Cell Lung Carcinoma cohort
Other indications for Durvalumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P2 | BB · 70 |
| Primary Peritoneal Carcinoma | — | P2 | BB · 70 |
| Urothelial Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Durvalumab in Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/durvalumab-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →